Breaking News Instant updates and real-time market news.

CAT

Caterpillar

$88.92

0.7 (0.79%)

, CMI

Cummins

$130.84

2.67 (2.08%)

11:00
10/11/16
10/11
11:00
10/11/16
11:00

Goldman ups Caterpillar, Cummins to buy on upbeat margin outlook

The shares of Caterpillar (CAT) and engine maker Cummins (CMI) are climbing despite the down market after Goldman Sachs upgraded the stocks today. Both companies' margins should rise, wrote the firm, which also added Cummins to its Conviction List. CATERPILLAR: Caterpillar's margins should rise during the current cycle, enabling its earnings to reach $8 per share, wrote Goldman analyst Jerry Revich. The $8 EPS estimate is significantly above investors' expectations and the stock will rise significantly if Caterpillar is able to achieve that milestone, the analyst wrote. Moreover, the sentiment of both mutual funds and sell side analysts towards Caterpillar appears to be unenthusiastic, noted Revich, who estimated that the company's margins can reach 15%. Among the catalysts set to boost Caterpillar are increases in depressed mining equipment spending and the company's cost reductions, Revich wrote. He hiked his price target on the shares to $112 from $76. CUMMINS: Cummins' key end markets, including the U.S., the Chinese truck market, and mining and energy, "are approaching bottom," Revich believes. In China, the medium and heavy truck market bottomed in the first half of this year, the analyst reported. Meanwhile, new electronic logging regulations in the U.S. should lower truckers' overtime, reducing supply by 4% and eventually driving up truck prices, the analyst stated. Additionally, Cummins is taking several steps that will reduce its manufacturing costs, Revich believes. He raised his price target on the shares to $162 from $134. WHAT'S NOTABLE: In the same note, Revich downgraded Martin Marietta (MLM) and Summit Materials (SUM), both to Neutral from Buy, citing expectations for slowing growth in the fourth year of the construction recovery. Revich also downgraded KBR to (KBR) Sell from Neutral, citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. PRICE ACTION: In late morning trading, Caterpillar added 0.5% to $88.69 and Cummins gained 1.9% to $130.62 per share.

CAT

Caterpillar

$88.92

0.7 (0.79%)

CMI

Cummins

$130.84

2.67 (2.08%)

MLM

Martin Marietta

$169.86

-1.39 (-0.81%)

SUM

Summit Materials

$18.57

-0.42 (-2.21%)

KBR

KBR

$15.27

-0.9899 (-6.09%)

  • 25

    Oct

CAT Caterpillar
$88.92

0.7 (0.79%)

09/19/16
OTRG
09/19/16
DOWNGRADE
OTRG
Mixed
Caterpillar downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Caterpillar to Mixed saying Q3 global new heavy equipment orders are down 8-11% year-over-year on weakness in North American. The firm said EMEA North American used equipment availability is looser and dealers expect further used pricing pressures as large volumes of leased machines are returned to Caterpillar Financial.
09/19/16
09/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Hold from Buy at Canaccord with analyst Michael Graham saying he expects TPV growth to remain solid driven by Venmo and One Touch, but said these factors are well understood and reflected in estimates. 2. Viacom (VIA, VIAB) downgraded to Hold from Buy at Stifel with analyst Benjamin Mogil saying the stock's valuation is no longer attractive in the wake of the news that the company had decided to table its plans to sell a minority stake in Paramount. 3. Caterpillar (CAT) downgraded to Mixed from Positive at OTR Global with the firm saying third quarter global new heavy equipment orders are down 8%-11% year-over-year on weakness in North American. 4. Western Union (WU) downgraded to Negative from Neutral at Susquehanna with analyst James Friedman saying he is concerned about downside risks given the company's high multiple, increased regulatory scrutiny, and the lack of improvement in its Middle East business. 5. Campbell Soup (CPB) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
GSCO
10/11/16
UPGRADE
Target $112
GSCO
Buy
Caterpillar upgraded to Buy from Neutral at Goldman
Goldman analyst Jerry Revich upgraded Caterpillar to Buy and raised its price target to $112 from $76 based on expectations for structurally higher margins in this cycle. The analyst believes stabilization in capex budgets suggest eventual normalization in mining equipment share of capex budgets. Following, the completion of the tier 4 product cycle, Revich said Caterpillar's R&D/sales is at 30+ year highs at 5.2% of sales, driving his view of flat to down R&D spending in a recovery, which is a 5% tailwind to incremental margins. The analyst sees $8 in mid-cycle earnings, well ahead of investor expectations, and said mutual funds are broadly underweight Caterpillar shares.
10/11/16
10/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Hold from Sell at Evercore ISI with analyst Ken Sena citing the recent pullback in the shares. 2. Tyson Foods (TSN) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he thinks that the company's "strong underlying fundamentals" should enable its fiscal 2017 profits to beat expectations, and he says that the shares are undervalued. 3. Virgin America (VA) upgraded to Neutral from Underweight at JPMorgan with analyst Jamie Baker saying regulatory approval of the pending Alaska Air (ALK) takeover "remains more likely than not." 4. Cummins (CMI) was upgraded to Conviction Buy from Neutral and Caterpillar (CAT) was upgraded to Buy from Neutral at Goldman. 5. Carbonite (CARB) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Schwartz saying he sees "substantial upside" from current levels due to valuation and fundamentals. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMI Cummins
$130.84

2.67 (2.08%)

09/07/16
09/07/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Navistar (NAV) initiated with a Hold at Deutsche Bank. 2. Barrick Gold (ABX) initiated with a Sell at Berenberg while the firm initiated Randgold (GOLD), Kinross Gold (KGC), and Goldcorp (GG) with a Hold. 3. 3. After the close on Tuesday, Deutsche Bank analysts Nicole DeBlase, Saree Boroditsky, and Kevin Marek initiated the U.S. Machinery group with a "cautious view." Oshkosh (OSK), Caterpillar (CAT), and Wabtec (WAB) were initiated with Buy ratings at Deutsche Bank, while the firm initiated Cummins (CMI) and CNH Industrial (CNHI) with Sell ratings. The firm also initiated Deere (DE), AGCO (AGCO), Terex (TEX), PACCAR (PCAR), WABCO (WBC), and United Rentals (URI) with Hold ratings. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
LYON
09/30/16
INITIATION
Target $150
LYON
Buy
Cummins initiated with a Buy at CLSA
CLSA analyst Kristine Kubacki initiated Cummins with a Buy and a $150 price target. The analyst Cummins is nearing deep trough levels in many of its end markets and expects a recovery in major North American and industrial end markets in 2018.
10/11/16
GSCO
10/11/16
UPGRADE
Target $162
GSCO
Conviction Buy
Cummins upgraded to Conviction Buy from Neutral at Goldman
Goldman analyst Jerry Revich upgraded CMI to Conviction Buy from Neutral saying he expects structurally higher margins in this cycle. The analyst said key end markets are bottoming, margins are well above prior cycle trough, and sees further upside to margin expectations driven by the Power Systems restructuring. Revich raised Cummins' price target to $162 from $134 based on mid-cycle valuation and the catalyst of new electronic logging standards that suggest potential US and international truck demand should begin to normalize.
MLM Martin Marietta
$169.86

-1.39 (-0.81%)

05/09/16
SPHN
05/09/16
NO CHANGE
Target $200
SPHN
Overweight
Martin Marietta price target raised to $200 from $179 at Stephens
Stephens analyst Trey Grooms raised his price target for Martin Marietta to $200 from $179 following the company's "strong" Q1 results, coming in ahead of expectations in every category. The analyst reiterates an Overweight rating on the shares.
10/11/16
GSCO
10/11/16
DOWNGRADE
GSCO
Neutral
Martin Marietta downgraded to Neutral from Buy at Goldman
Goldman analyst Jerry Revich downgraded Martin Marietta to Neutral citing valuation and expectations for slowing growth in the 4th year of the construction recovery. The analyst said the US public construction recovery is slowing and private non-residential construction is slowing as chemicals and LNG peak. The analyst lowered his price target to $202 from $210 on Martin Marietta shares.
05/09/16
05/09/16
NO CHANGE

Martin Marietta Q1 results 'impressive,' says Sterne Agee CRT
Sterne Agee CRT believes that Martin Marietta reported "impressive" Q1 results, and it says the company's comments were "positive." Sterne says it's "more fired up about the medium-term outlook for the aggregates industry than" it's been in a decade. The firm raised its price target on the name to $202 from $192 and keeps a Buy rating on the shares.
02/10/16
VERT
02/10/16
UPGRADE
VERT
Buy
Martin Marietta upgraded to Buy from Hold at Vertical Research
SUM Summit Materials
$18.57

-0.42 (-2.21%)

02/17/16
02/17/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ocular Therapeutix (OCUL) upgraded to Overweight at Morgan Stanley by analyst Andrew Berens, who said the company's management provided a pathway forward for OTX-TP in glaucoma that appears to be a much lower bar than expected. 2. Carlyle Group (CG) upgraded to Overweight at Morgan Stanley, with analyst Michael Cyprys citing compelling risk/reward and near-term catalysts that include the $4B in portfolio exit pipeline, a $4B investment deployment pipeline, a $200M buyback program, cost controls, and focus on more scalable fund strategies. 3. Tyson Foods (TSN) upgraded to Overweight by Stephens analyst Farha Aslam, who said its valuation multiple should move up since its earnings growth and stability, balance sheet and product portfolio are mirroring that of consumer packaged food companies. 4. Tyler Technologies (TYL) upgraded to Buy at B. Riley, with analyst Kevin Liu citing the New World Systems (NWS) acquisition and expects results and guidance to compare favorably to his estimates. 5. Summit Materials (SUM) upgraded to Buy at Citi by analyst Scott Schrier, who cited attractive valuation and a "constructive outlook" for the heavy materials space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
GSCO
10/11/16
DOWNGRADE
GSCO
Neutral
Summit Materials downgraded to Neutral from Buy at Goldman
Goldman analyst Jerry Revich downgraded Summit Materials to Neutral based on expectations for slowing growth in the 4th year of the construction recovery. The analyst lowered his price target to $21 from $22 on Summit shares.
02/17/16
SBSH
02/17/16
UPGRADE
Target $21
SBSH
Buy
Summit Materials upgraded to Buy from Neutral at Citi
Citi analyst Scott Schrier upgraded Summit Materials to Buy citing an attractive valuation and a "constructive outlook" for the heavy materials space. The analyst has a $21 price target for the shares.
04/01/16
RBCM
04/01/16
NO CHANGE
RBCM
Summit Materials price target raised to $23 from $18 at RBC Capital
After meeting with Summit's CFO, RBC Capital thinks that the stock can rise based on what it sees as potential improving price/volume trends, margin expansion, and strategic M&A. RBC keeps an Outperform rating on the shares.
KBR KBR
$15.27

-0.9899 (-6.09%)

10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
GSCO
10/11/16
DOWNGRADE
Target $15
GSCO
Sell
KBR downgraded to Sell from Neutral at Goldman
Goldman analyst Jerry Revich downgraded KBR to Sell citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. The analyst lowered his price target to $15 from $16.
10/05/16
10/05/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UBS (UBS) upgraded to Sector Perform from Underperform at RBC Capital with analyst Fiona Swaffield saying she sees a dividend reduction as unlikely and believes expectations for the bank's Wealth Management business are now lower. 2. Parker-Hannifin (PH) upgraded to Buy from Hold at Stifel with analyst Nathan Jones saying distributors expect to see revenue growth declining 2% in the second quarter of fiscal 2017 which he believes should be enough for Parker to see its first positive year-over-year revenue comp company wide in six quarters. 3. Flex (FLEX) upgraded to Conviction Buy from Buy at Goldman with analyst Mark Delaney saying it is positioned to benefit from entry into new markets and valuation looks attractive. 4. KBR (KBR) upgraded to Accumulate from Hold at Johnson Rice with analyst Martin Malloy citing the recent pullback in shares and said the stock multiple should trend higher given the shift in business mix to more low-risk, cost reimbursement revenues. 5. Plains All American (PAA) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
JRCO
10/05/16
UPGRADE
Target $18
JRCO
Accumulate
KBR upgraded to Accumulate from Hold at Johnson Rice
Johnson Rice analyst Martin Malloy upgraded KBR to Accumulate with an $18 price target citing the recent pullback in shares and said the stock multiple should trend higher given the shift in business mix to more low-risk, cost reimbursement revenues.

TODAY'S FREE FLY STORIES

CELG

Celgene

$117.63

-1.24 (-1.04%)

22:25
12/04/16
12/04
22:25
12/04/16
22:25
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

AAPL

Apple

$109.90

0.41 (0.37%)

, ALNY

Alnylam

$41.57

-0.01 (-0.02%)

21:48
12/04/16
12/04
21:48
12/04/16
21:48
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$109.90

0.41 (0.37%)

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

UTX

United Technologies

$108.22

0.74 (0.69%)

RXN

Rexnord

$20.27

-0.72 (-3.43%)

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

EVC

Entravision

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

DE

Deere

$101.50

-1.2 (-1.17%)

ARCH

Arch Coal

$79.32

1.6 (2.06%)

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

MRK

Merck

$61.13

0.37 (0.61%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 15

    Jan

  • 08

    Mar

  • 13

    Mar

TRIP

TripAdvisor

$46.46

-0.7 (-1.48%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$85.62

0.15 (0.18%)

21:40
12/04/16
12/04
21:40
12/04/16
21:40
Upgrade
Citrix rating change  »

Citrix upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 08

    Dec

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.